Back to All Combinations
HER2-Low
Intermediate PrognosisGenes Involved
HER2
Treatment Implications
Emerging category. T-DXd trials ongoing in CRC.
Recommended Treatments
Standard therapy
Clinical trials
Treatments to Avoid
No specific contraindications noted
Study References
DESTINY-CRC02
Key Statistics
15.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Keep patients in mind for emerging trials.
Information
Category: HER2 Pathway
Evidence Level: Level 3
Last Updated: Dec 7, 2025
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.